This document assesses the risk to human health posed by a multi-country foodborne outbreak of Shiga toxin-producing Escherichia coli (STEC) infections associated with haemolytic uraemic syndrome taking place in the European Union (EU).
This risk assessment summarises the development of the 2015–16 influenza season, which so far has been characterised by a prevalence of type A viruses.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
This update was prompted in order to reassess the risk for European travellers to South Korea now that there have been no additional cases reported since 4 July 2015.
This risk assessment was triggered by a large cluster of confirmed MERS-CoV cases in South Korea, generated by a primary case imported from the Middle East. This is the largest cluster observed outside of the Arabian Peninsula so far.
Human cases and fatalities due to influenza A(H5N1) virus continue to increase in Egypt, with cases from the country now accounting for the highest number of human cases reported worldwide.
Since April 2012 and as of 7 March 2015, 1 082 cases (including 439 deaths) of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported by local health authorities worldwide.
This rapid risk assessment summarises the epidemiological and virological information about human infections with low pathogenic avian influenza A(H7N7) viruses and assesses the risk to public health in the EU/EEA, in response to this outbreak.